CELZ (Creative Medical Technology Holdings) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CELZ Creative Medical Technology Holdings Inc CELZ
28 GF Score
Price $0.88
GF Value $0.48
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings Net Loan?

Net Loan only applies to banks and insurance companies.

CELZ
28GF Score
Creative Medical Technology Holdings Inc CELZ
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $0.88 is trading 83.4% above its estimated GF Value™ of $0.48. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • Net Loan:
  • GF Value™: $0.48 vs. price of $0.88 (83.4% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc. is a clinical-stage biotechnology company developing cell-based regenerative therapies across immunology, endocrinology, urology, neurology, and orthopedics. Its pipeline includes CELZ-201 (AlloStem), an allogeneic perinatal tissue-derived cell therapy being studied for recent-onset Type 1 diabetes and other indications; CELZ-100 (ImmCelz), a personalized immune modulation platform; and CELZ-001 (AmniStem), a perinatal-derived cell program. The company also has earlier-stage programs targeting conditions such as premature ovarian failure, erectile dysfunction, chronic lower back pain, and kidney and liver disease. Creative Medical Technology pursues development both independently and through strategic partnerships and licensing arrangements, and it has historically generated limited revenue from regenerative medicine products and services offered through affiliated clinics. The company is headquartered in Phoenix, Arizona, and its activities are concentrated in the United States.
28GF Score

Get the complete analysis for CELZ

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.88
Price
$0.48
GF Value